✦ LIBER ✦

The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus

✍ Scribed by van Poppel, P.C.M.; Gresnigt, M.S.; Smits, P.; Netea, M.G.; Tack, C.J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The dipeptidyl peptidase-4 inhibitor PHX

✍ G. Garcia-Soria; G. Gonzalez-Galvez; G. M. Argoud; M. Gerstman; T. W. Littlejohn 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB

Efficacy, safety and dose-response relat

✍ Kadowaki, T.; Kondo, K. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 649 KB

Efficacy and safety of the dipeptidyl pe

✍ I. Raz; M. Hanefeld; L. Xu; C. Caria; D. Williams-Herman; H. Khatami; Sitaglipti 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 160 KB

Comparison of the dipeptidyl peptidase-4

✍ Hassanein, Mohamed; Hanif, Wasim; Malik, Waqar; Kamal, Ali; Geransar, Parnia; Li 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 232 KB

The efficacy and safety of the dipeptidy

✍ Robert Frederich, Robert McNeill, Niklas Berglind, Douglas Fleming, Roland Chen 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 239 KB

Efficacy and safety of the dipeptidyl pe

✍ K. Hermansen; M. Kipnes; E. Luo; D. Fanurik; H. Khatami; P. Stein; Sitagliptin S 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB